Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, approved on October 17, 2022, involve options to purchase 87,400 shares of common stock, with an exercise price of $5.63 per share, reflecting the closing stock price on the grant date. The options have a ten-year term and vest over four years. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. This decision, made on September 15, 2022, complies with Nasdaq Listing Rule 5635(c)(4). The new employees received options to purchase a total of 125,000 shares of common stock, at an exercise price of $6.34 per share. The options have a ten-year term and will vest over four years, with the first 25% vesting on the first anniversary of their employment.
Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. Approved on August 16, 2022, the awards total 172,000 shares of common stock in options with a ten-year term and an exercise price of $5.83. Vesting will occur over four years, starting 25% on the first anniversary of employment. Annexon is dedicated to developing innovative complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.
Annexon, a clinical-stage biopharmaceutical company focused on complement-mediated diseases, reported significant progress with five clinical-stage candidates following recent Phase 1 trial initiations for ANX105 and ANX1502. The company secured approximately $130 million in a private placement, extending its operating runway into the second half of 2025. The FDA granted Fast Track designation for ANX007 targeting geographic atrophy. Despite a net loss of $37.1 million in Q2 2022, the promising pipeline and anticipated clinical milestones are set to drive future growth.
Annexon, Inc. (Nasdaq: ANNX) has completed a private placement, raising approximately $130 million to support its clinical pipeline of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders. This funding will extend the company’s operational runway into the second half of 2025. The placement includes the sale of 9,013,834 shares and pre-funded warrants at prices around $3.87 per share. Major investors include Redmile Group, Adage Capital, and Bain Capital. Annexon aims to advance its first oral complement agent, ANX1502.
Annexon, a clinical-stage biopharmaceutical company, announced a private placement expected to raise approximately $130 million before fees. The placement involves selling 9,013,834 shares of common stock and warrants, priced at $3.871250 per share. Major investors include Redmile Group and Adage Capital. The deal will close on July 11, 2022, pending customary conditions. The company is committed to filing a registration statement for resale of the shares, aligning with Nasdaq regulations.
Annexon (Nasdaq: ANNX) announced positive final data from its Phase 2 clinical trial of ANX005 for Huntington’s disease (HD), showing complete C1q target inhibition and stabilization of disease progression over nine months. Of 28 participants, 23 completed the study, demonstrating sustained clinical benefits in patients with high baseline complement activity. The treatment was generally well-tolerated, with no serious adverse events reported. These results highlight ANX005’s potential as a novel therapy for HD, addressing a critical unmet need in the field.
Annexon (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET in New York City. The event is part of Annexon's effort to showcase its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's Investors page, with a 30-day replay option.
Annexon is developing a diverse pipeline aimed at treating classical complement-mediated diseases.
Annexon, Inc. (Nasdaq: ANNX) announced plans to present data from its complement-targeted pipeline at various medical meetings this summer. The company focuses on developing treatments for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Key presentations include topics related to lupus nephritis and warm autoimmune hemolytic anemia, scheduled for June 2022. Annexon's approach aims to inhibit C1q, offering potential protection against diseases impacted by the classical complement pathway, with clinical data expected throughout 2022 and 2023.
Annexon, a clinical-stage biopharmaceutical company, reported progress across its pipeline and first quarter 2022 financial results. With a broad portfolio of five candidates targeting complement-mediated disorders, Annexon anticipates eight clinical catalysts in 2022-2023. The lead candidate, ANX005, shows promise in treating Guillain-Barré Syndrome and Huntington's disease, demonstrating rapid clinical improvements. As of March 31, 2022, cash reserves totaled $206.7 million, sufficient to fund operations into 2024. However, the company reported a net loss of $35.4 million, reflecting increased expenses.